Navigation Links
Multi-Pronged Therapeutic Cancer Vaccine Regimen to be Studied in Melanoma Patients
Date:9/17/2008

PARIS, and TORONTO, Sept. 17 /PRNewswire/ -- Sanofi pasteur, the vaccines division of the sanofi-aventis Group, announced today that it is sponsoring a Phase II clinical study exploring a multi-pronged treatment approach to high risk and advanced-stage melanoma -- an often fatal form of cancer for which there are limited treatment options. Patients are being enrolled in the United States and Canada. The trial, called MEL11, will investigate the safety and efficacy of a therapeutic cancer vaccine regimen aimed at stimulating the body's immune system to fight melanoma.

"The MEL11 study uses an entirely new treatment approach to advanced-stage melanoma," said Teresa Petrella, MD, Medical Oncologist and Clinical Researcher at the Odette Cancer Centre at the Sunnybrook Health Sciences Centre in Toronto and the lead investigator of the trial. "The study protocol combines the use of a vaccine with more traditional anti-cancer agents to bolster the effectiveness of the immune system. Melanoma is an increasing concern in the cancer community; its incidence is on the rise and there are very few available treatment options."

The vaccine candidate is uniquely designed to stimulate the body's own defenses -- the immune system -- to find and fight cancer cells. It makes use of a modified canarypox virus, ALVAC(2), which has been shown in an extensive body of research to promote immune responses in humans. The ALVAC(2) virus contains the genes for five antigens -- molecules that induce an immune response -- that are commonly found in melanoma tumors. These antigens stimulate T-cells within the immune system to hone in on melanoma cells, and are expected to halt or slow cancer progression. The vaccine also contains the genes for three proteins called co-stimulatory molecules, which increase the immune response of T-cells to the antigens. In addition to the vaccine, patients in this trial will be treated with two other agents that augment the immune response: GM
'/>"/>

SOURCE sanofi pasteur
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX
10. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... OAKS, Calif. , Jan. 15, 2014 ... Amgen (NASDAQ: AMGN ) announced today ... jointly discover and validate new therapeutic targets and ... a chronic disorder that affects millions worldwide. The ...
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
(Date:1/15/2014)... 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ... CGM System as a non-invasive, wireless continuous glucose monitoring ... Executive Chairman and Interim CEO of Echo Therapeutics, will ... Equity Conference. Mr. Doman will make ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... , WESTON, Fla. , June 15 DHL ... the needs of mail-order pharmacies. DHL SMARTMAIL PHARMA SELECT ™ ... of serving the pharmaceutical industry. Thanks to this expertise and Global ... with greater accountability and value. , ...
... June 15 Solos Endoscopy, Inc. (Pink ... has developed a relay lense adapter system for its ... scope and endocoupler to join with virtually all video ... the flexibility to market the MammoView® to those customers ...
Cached Medicine Technology:DHL Global Mail Launches Specialized Shipping Service for Mail-Order Pharmacies 2Solos Endoscopy, Inc. Develops Relay Lense Adapter System For MammoView® Product Line 2
(Date:4/18/2014)... 160 years of neuroanatomy on its head. , Myelin, ... for the fast transmission of impulses along the axons ... according to a new work lead by Professor Paola ... the University,s Department of Stem Cell and Regenerative Biology, ... of Molecular and Cellular Biology. , "Myelin is a ...
(Date:4/18/2014)... Simon Fraser University psychologists have made a brain-related ... of attention-deficit disorders. , This discovery opens up ... hinder or suppress a specific brain activity that ... distraction. , The Journal of Neuroscience ... by John McDonald, an associate professor of psychology ...
(Date:4/17/2014)... inflammation in benign prostate tissue was associated with ... was found even in those with low prostate-specific ... in Cancer Epidemiology, Biomarkers & Prevention , ... Research. , An analysis of prostate tissue biopsies ... of the Prostate Cancer Prevention Trial (PCPT) found ...
(Date:4/17/2014)... Ill. One of the most popular vaccine brands ... And doctors may be overlooking some cost factors when ... a more expensive option, according to a new study ... vaccines to administer can be driven by numerous factors," ... and a professor of computer science and of mathematics ...
(Date:4/17/2014)... 2014) Two recent papers by a University ... may help scientists develop treatments or vaccines for ... encephalitis and other disease-causing flaviviruses. , Jeffrey S. ... genetics at the School of Medicine and an ... Institute, and colleagues recently published articles in the ...
Breaking Medicine News(10 mins):Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2
... Drills and Anesthesia are the instruments dentists’ swear by, what ... to drill// a tooth to treat decay? While you can ... early man could have tapped, researchers have dug up the ... flint head served the purpose of a drill. ...
... one of the world’s poorest country, more than a month ... near its southern border with Nigeria. ,The semi-desert former ... areas on February 28, the day after an outbreak of ... as it lacked the resources to do the job. ...
... administering noxious substance to the patient in the hospital. The woman ... to give lethal doses of drugs to the patient. ... is a member of medical staff but not a qualified nurse. ... bail to return on Wednesday, 17 May. ,The woman, ...
... Tropical cyclone Glenda has increased the spread of the ... Western Australian regions, Kimberley and Pilbara. ,The ... that causes Murray Valley encephalitis (MVE). The cyclone Glenda ... mosquito breeding grounds. ,The Department of Health ...
... According to a recent Florida State University study, hospitals ... in IT// for all hospital operations. ,According ... hospitals, Manatee Memorial and Lakewood Ranch Medical Centre, have ... last few years. He said that, the hospitals are ...
... the medicine metformin is taken once daily it is safe ... words of co-author Dr. Bret Berner, "With this extended-release formula, ... day. The new formulation, which goes by the brand name ... ,Dr. Bret Berner is chief scientific officer and vice ...
Cached Medicine News:Health News:Delayed Start By Niger On Culling Of Poultry 2Health News:Delayed Start By Niger On Culling Of Poultry 3Health News:Technology Can Help Fight Health Care Costs 2Health News:Technology Can Help Fight Health Care Costs 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: